0.74
-3.25%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Milestone Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Milestone Pharmaceuticals is based in Montreal, Quebec, Canada and is incorporated in Quebec, Canada. Its shares trade on Nasdaq under the ticker MIST. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $63.1m. At that date it held total assets of $113.6m and shareholders' equity of $41.8m.
We are currently focusing our efforts and financial resources on (i) the commercialization of CARDAMYSTTM (etripamil) nasal spray for the treatment of PSVT, (ii) the development of etripamil for the treatment of AFib-RVR and (iii) corporate development activities that have the potential to increase company value through strategic collaborations.
On December 12, 2025, we announced that the FDA approved our first commercial product, CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of PSVT, to sinus rhythm in adults. We are focused on the commercialization of CARDAMYST, which became available in retail pharmacies in the first quarter of 2026. We manufacture CARDAMYST with a global supply chain that produces the active pharmaceutical ingredient, etripamil, and then formulates and assembles it into the delivery device, a nasal spray, before completing packaging of the saleable product which is then distributed via a third party logistics provider to wholesalers for delivery to retail pharmacies once prescriptions are received. To create demand, our sales team of approximately 60 representatives expects to engage healthcare providers who we believe will treat around 500,000 patients with a diagnosis of PSVT in 2026.
Quoted from its 10-K, filed 20 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 9 May 2019
- Employees
- 38
- Website
- milestonepharma.com ↗
- Head office
- 1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, A8, H4M 2X6
- Incorporated in
- A8
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Robert WillsNon-Executive Independent Chairman of the Board$135,142
- Mr. Joseph OlivetoPresident, Chief Executive Officer, Director, since 2017$982,296
- Mr. Amit HasijaChief Financial Officer, Executive Vice President - Corporate Development$601,517
- Mr. Jeffrey NelsonChief Operating Officer
- Mr. David SandovalGeneral Counsel, Chief Compliance Officer
- Dr. David BharuchaChief Medical Officer$636,174
- Mr. Lorenz MullerChief Commercial Officer
- Mr. Stuart DutyIndependent Director$160,492
- Mr. Seth FischerIndependent Director$101,892
- Ms. Lisa GilesIndependent Director$108,642
- Mr. Joseph PapaIndependent Director$100,035
- Mr. Andrew SaikIndependent Director$162,992
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Milestone Pharmaceuticals Inc possesses several strengths that contribute to its competitive advantage:
Weaknesses
- Despite its strengths, Milestone Pharmaceuticals Inc also faces certain weaknesses that may hinder its growth and success:
Opportunities
- The following opportunities can positively influence the growth prospects of Milestone Pharmaceuticals Inc:
Threats
- Milestone Pharmaceuticals Inc is exposed to several external threats that pose challenges to its business operations:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.